BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 6, 2023
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» Fujian Akeylink Biotechnology identifies new Mpro inhibitors for SARS-CoV-2 infection
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Infection
Fujian Akeylink Biotechnology identifies new Mpro inhibitors for SARS-CoV-2 infection
July 20, 2023
No Comments
Fujian Akeylink Biotechnology Co. Ltd. has prepared short peptide compounds containing β-aminoketone and characterized as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors.
BioWorld Science
Infection
Coronavirus
Patents
